Loading
Life sciences · Journal article
The Journal of Dermatological Treatment · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objectives. Systemic therapies have transformed dermatologic practice by providing effective treatment for several conditions, including autoimmune diseases, inflammatory disorders, and severe cutaneous emergencies. Despite their therapeutic benefits, these agents may cause psychiatric adverse effects that complicate clinical management.Methods. We conducted an initial literature review synthesizing psychiatric adverse effects of systemic dermatologic medications-including corticosteroids, immunosuppressants, Janus kinase inhibitors, antihistamines, antimalarials, dapsone, isotretinoin, and biologics-and proposed a clinical framework for the screening and monitoring of these complications.Results. Psychiatric adverse effects vary across systemic therapies. Corticosteroids are associated with mood disturbances, psychosis, and delirium, with psychiatric symptoms occurring in nearly 20% of patients receiving high-dose therapy. Isotretinoin remains controversial because of its potential association with depression and suicidality. Other systemic agents have been reported to cause a range of neuropsychiatric effects, although the frequency and strength of evidence differ among medications.Conclusions. Overall, psychiatric adverse effects represent an important consideration in the use of systemic dermatologic therapies. Awareness of these potential complications, coupled with appropriate screening and monitoring, is essential for early recognition and effective management. Improved understanding of medication-related psychiatric effects can help dermatologists optimize treatment outcomes while enhancing patient safety.